RECCAN AB Secures SEK 7 Million Investment to Advance Groundbreaking Pancreatic Cancer Test Towards Market
Anna Brodén, CEO of RECCAN ABLund, Sweden – RECCAN AB has secured SEK 7 million through a directed share issue, with Sandberg Development as the lead investor. The capital will fund clinical validation and verification of production processes ahead of CE marking and a European launch. The share issue, which included participation from existing shareholders, reflects continued strong confidence in the company’s vision and technological platform.
RECCAN is developing a blood-based test for early detection of pancreatic cancer, aiming to enable earlier diagnosis and thereby improve treatment outcomes and quality of life. Through a simple blood sample, the company seeks to provide an effective tool for identifying cancer at an early stage—when treatment is most effective.
“Leaving the development phase behind is a major milestone for us,” said Anna Brodén, CEO of RECCAN AB. “This capital injection allows us to ensure the quality and scalability needed for a successful market launch.”
With funding in place, RECCAN is well-positioned to enter the validation and regulatory phase and take further steps toward improving early detection and outcomes for one of the deadliest forms of cancer.
“Our test has the potential to revolutionize both diagnosis and care for pancreatic cancer. We are pleased that our investors share our long-term vision,” Brodén concluded.
RECCAN is a member of SmiLe's incubator program.
For more information, please contact:
Anna Brodén, CEO of RECCAN AB, anna.broden@reccandiagnostics.com
+46 (0)70-293 70 22
www.reccandiagnostics.com
Read post on SmiLe Venture Hub – Pioneering Life Science and Foodtech Innovations newsroomVisit SmiLe Venture Hub – Pioneering Life Science and Foodtech Innovations newsroom
About SmiLe newsroom
SmiLe is a leading venture hub that specializes in advancing life science and foodtech startups from concept to commercialization. We offer comprehensive support through every stage of entrepreneurship, including tailored incubation and acceleration programs, a variety of educational courses, and access to top-tier lab facilities. To date, our flagship incubator program has supported over 110 startups, facilitating their collective acquisition of more than EUR 1.05 billion in venture capital and contributing to 21 successful IPOs. Recognized as one of Europe’s leading startup hubs in 2024 by the Financial Times and Statista, SmiLe continues to be a catalyst for innovation in the life sciences sector. As a non-profit entity based in Lund, Sweden, SmiLe is supported by Region Skåne, Lund Municipality, Lund University, and Medicon Village. We are also backed by our partners Agilent, Sparbanken Skåne, Høiberg, Setterwalls, Zacco, Key2Compliance, Phase Holographic Imaging, ChemoMetec, Samplix, Qiagen, Merck, Bio-Rad, Zeiss, SmartStone Nordics, and AbbVie Scandinavia. For more information: www.smileventurehub.com